CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer.
The company was founded in 2016 with headquarters in California with international partners. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational agents in well established pathways that restore the body’s immune system to recognize and kill cancer cells.
To be a global leader in developing novel medicines for cancer patients and improving lives.
To develop novel oncology medicines to improve the lives of those living with life-threatening malignancies.
We will pursue this mission by developing and commercializing treatment solutions as rapidly and diligently as possible for patients and the people who care for them.
We will perform our work with persistence and sense of urgency, with integrity and scientific excellence as our guiding principles at all times.
By fostering individual performance, teamwork and the spirit of partnership, we will achieve our goal – to deliver life-saving oncolytic therapeutics to patients who suffer today.